Skip to main content
Equibles
BIIB logo

BIIB · Biogen Inc. · Metrics

Track BIIB — free

Use BIIB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BIIB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$243.15 +9.67 (+4.14%)
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$34.77B
Shares
147.64M
Volume · Oct 20 942.65K Avg daily vol (3M) 997.42K

BIIB metrics

105 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$233.48
Market cap
$34.77B

Price action

20 metrics
Price change (1W)
+1.8%
Price change (30D)
+6.6%
Price change (3M)
+16.8%
Price change (6M)
+27.3%
Price change (YTD)
+32.7%
Price change (1Y)
+63.3%
Trailing year
Price change (5Y)
-12.9%
52-week high
$235.35
52-week low
$146.22
Change from 52-week high
-0.8%
Change from 52-week low
+59.7%
Annualized volatility
33.5%
Annualized volatility (3M)
25.7%
Beta
0.3
RSI (14D)
62.3
Price vs SMA 50
+6.0%
Price vs SMA 200
+17.9%
Avg volume (3M)
997,424
Relative volume
1.0
Average dollar volume
$216.91M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - General
Shares outstanding
147.64M

Valuation

12 metrics
P / E (TTM)
41.5
Trailing earnings · reciprocal yield 2.4%
PEG ratio
—
EV / revenue
4.1×
reciprocal yield 24.6%
EV / EBITDA
13.1×
reciprocal yield 7.6%
EV / EBIT
15.9×
reciprocal yield 6.3%
P / sales
3.5×
reciprocal yield 28.8%
P / book
1.8
reciprocal yield 54.2%
FCF yield
7.8%
TTM · current market cap
Buyback yield
—
P / FCF
12.9
reciprocal yield 7.8%
P / operating cash flow
12.1
reciprocal yield 8.3%
Earnings yield
2.4%

Historical valuation

8 metrics
P / E historical average (3Y)
17.5×
reciprocal yield 5.7%
P / E historical average (5Y)
17.9×
reciprocal yield 5.6%
EV / revenue historical average (3Y)
3.1×
reciprocal yield 32.3%
EV / revenue historical average (5Y)
3.4×
reciprocal yield 29.8%
EV / EBIT historical average (3Y)
15.0×
reciprocal yield 6.7%
EV / EBIT historical average (5Y)
13.9×
reciprocal yield 7.2%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-10-28
Last earnings
2026-07-29

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
8.3%
Gross profit (TTM)
$11.64B
Operating profit (TTM)
$2.48B
Net income (TTM)
$834.60M
Trailing 12 months
Diluted EPS (TTM)
$5.63
FCF margin
26.9%
Effective tax rate
17.5%

Per share

11 metrics
Revenue per diluted share (TTM)
$67.73
Gross profit per diluted share (TTM)
$72.08
Operating profit per diluted share (TTM)
$16.70
EBITDA per diluted share (TTM)
$20.26
Net income per diluted share (TTM)
$5.65
Operating cash flow per diluted share (TTM)
$19.48
Free cash flow per diluted share (TTM)
$18.25
Capital expenditures per diluted share (TTM)
$1.23
R&D per diluted share (TTM)
$13.60
Stock compensation per diluted share (TTM)
$2.00
Book value per share
$124.37

Growth

11 metrics
Revenue growth YoY
+3.4%
Year over year
Net income growth YoY
-84.6%
Revenue (TTM)
$10.03B
Trailing 12 months
EPS growth YoY
-84.8%
Shares change YoY
+1.4%
Year over year · more shares
Revenue CAGR (3Y)
-0.9%
Revenue CAGR (5Y)
-6.0%
EPS CAGR (3Y)
-25.0%
EPS CAGR (5Y)
-18.7%
FCF CAGR (3Y)
+21.5%
FCF CAGR (5Y)
-11.6%

Quality

14 metrics
Return on equity
4.4%
Return on assets
2.6%
Debt / equity
0.4
Current ratio
1.9
EBITDA (TTM)
$3.01B
Free cash flow (TTM)
$2.70B
Quick ratio
1.3
Interest coverage
—
Net debt / EBITDA
1.5
Return on invested capital
—
Trailing 12 months
Net cash
−$6.01B
Latest balance sheet
Cash & equivalents
$1.28B
Total assets
$32.09B
Total debt
$7.29B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$2.88B
Capital expenditures (TTM)
$182.20M
R&D (TTM)
$2.01B
SG&A (TTM)
$2.59B
Stock compensation (TTM)
$296.30M
R&D / revenue
20.1%
Stock compensation / revenue
3.0%

Ownership (13F)

9 metrics
13F filers
1,057
13F filer change QoQ
+36
Institutional ownership
99.6%
Conviction holders (share of 13F filers)
0.9%
Crowding (high-turnover and private-fund holders)
11.9%
Private-fund adviser ownership
11.5%
Active holders' share change QoQ
+5.1%
Holder tenure
18.7
Price vs estimated holder cost
+28.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
22.9%

Short interest

3 metrics
Short interest
4.0%
Latest settlement · 4.9 days to cover
Days to cover
4.9d
Short-squeeze score
65 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$239,750
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 875045 CUSIP 09062X103 13F (30d) 163 filings 148 filers Visit website Investor relations